Why Is ABBOTT LABS (ABT) Stock Up Today?

ABBOTT LABS shares rose 10.71% to $98.83 on Thursday, driven by a strong earnings report and raised guidance. The company reported second quarter 2026 results that beat expectations, with improved margins and solid organic growth. The stock’s sharp rise reflects renewed confidence in the firm’s performance and its strategic direction following the Exact Sciences acquisition.

What Happened

Abbott Laboratories reported Q2 2026 earnings of $1.31 per share, exceeding forecasts and raising its full-year adjusted earnings guidance to a range of $5.45 to $5.60. The company highlighted broad-based momentum across its business segments and announced key product launches. The improved financial results and strategic clarity have eased concerns about integration costs from the Exact Sciences acquisition, prompting a strong positive reaction from investors. The stock’s performance also benefited from a recent acquisition that is already showing measurable results, according to analysts.

What The Data Shows

The stock’s 10.71% gain pushed it above its 100-day moving average and marked one of its best days in recent memory. Over the past eight sessions, ABT has risen 4.2%, from $95.84 to $99.84. The company’s fundamentals show a market cap of $160.4 billion, a P/E ratio of 25.0, and trailing twelve-month revenue growth of 6.6%. Recent insider transactions include a purchase by director Stratton John G on May 7. Congressional trades show mixed activity, with Rep. Ro Khanna buying and selling small positions in June and July.

What To Watch

With its Q2 2026 earnings call already completed, investors should focus on the company’s ability to maintain its momentum and meet the raised guidance. Continued product launches and integration progress from the Exact Sciences acquisition will be key areas to monitor in the coming quarters.